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 2 
Abstract 26 
  27 
Background 28 
To end the global tuberculosis epidemic, latent tuberculosis infection (LTBI) must be tackled. All recommended 29 
standard LTBI treatments contain drugs to which multi-drug resistant (MDR-) Mycobacterium tuberculosis are 30 
resistant. Hence knowledge of the MDR-M.tb global LTBI burden will inform TB elimination policy-making.  31 
 32 
Methods  33 
By fitting a flexible statistical model to TB drug resistance surveillance and survey data collated by the World 34 
Health Organisation, we estimated national trends in the proportion of new TB cases that were MDR-TB. This 35 
was used as a proxy for the proportion of new infections due to MDR-M.tb and multiplied ARI trends from 36 
previous LTBI estimate work to generate MDR-M.tb ARI trends. These were used within a new cohort model to 37 
estimate changing levels of latent infection with MDR-M.tb (MDR-LTBI). We report global and national 38 
prevalence of MDR-LTBI, as well as estimating recent infection levels and making predictions of the future 39 
burden in 2035 and 2050.  40 
 41 
Findings 42 
We found that 19 [95% uncertainty interval (UI): 16-22] million individuals carried MDR-LTBI in 2014. This 43 
represented 0·28% [95% UI: 0·24-0·31%] of the global population and 1·2% [95% UI: 1·0-1·4%] of all LTBI. 44 
Country prevalence ranged from 0·002% to 3·8% of the population. In those aged less than 15 years, the 45 
proportion of LTBI that is MDR was 2·9% [95% UI: 2·6-3·1%] (risk ratio compared to those over 15 years = 46 
2·65 [95% UI: 2·11-3·25]). Recent MDR-M.tb infection meant that 1·9 [95% UI: 1·7-2·3] million individuals 47 
globally in 2015 were at high risk of MDR-TB disease.  48 
 49 
Interpretation 50 
We estimate that three in every 1,000 people globally carry MDR-LTBI, resulting in one in every 83 individuals 51 
with LTBI carrying MDR-M.tb, and one in every 34 in those less than 15 years old. With current trends the 52 
proportion of LTBI that is MDR will increase, posing serious challenges for LTBI management, a cornerstone of 53 
TB elimination strategies. 54 
 55 
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Introduction 58 
 59 
The complex natural history of the world's biggest infectious disease killer, Mycobacterium tuberculosis (M.tb), 60 
means that for ultimate control those latently infected must be targeted.1,2 Currently, latent tuberculosis infection 61 
(LTBI) is defined as “a state of persistent immune response to stimulation by M. tb antigens with no evidence of 62 
clinically manifest active TB”.3 It has been estimated that 23% of the world's population could have LTBI and 63 
that even without ongoing transmission after 2014, reactivation disease would overwhelm the 2035 End TB 64 
Targets.4 Hence, understanding and targeting LTBI is a priority for TB elimination efforts,2 as recognised by the 65 
2018 UN High Level Meeting on TB.5 66 
 67 
Antimicrobial resistance (AMR) is an increasingly serious threat to global public health.6 Multidrug-resistant 68 
(MDR) strains of M.tb, which are resistant to both key first line TB drugs (rifampicin and isoniazid) cause 69 
approximately one in four of all AMR deaths.7 In 2017, MDR-TB contributed to over 10% of TB deaths globally.8 70 
MDR-TB patients experience low rates of appropriate diagnosis, low treatment success, and unacceptably long 71 
treatment regimens (>18months). MDR-TB already accounts for a disproportionally large fraction of the financial 72 
burden for TB control programmes. Preventing an increase of MDR-TB from a growing reservoir of MDR-LTBI 73 
(i.e. LTBI caused by MDR-M.tb strains) is therefore critical for the success of any TB control programme.  74 
 75 
Worryingly, MDR-M.tb are resistant to all currently recommended therapies prescribed to reduce the risk of 76 
progression to active disease for people with LTBI who are not known contacts of an MDR-TB patient.3 The 77 
priority population for LTBI testing and preventative therapy is currently household contacts of TB cases,9 likely 78 
to be infected by their household member, but in high incidence settings, infection may also frequently occur 79 
outside of the home.10 Due to such external transmission,11 and low detection (<30%) of MDR-TB cases,8 a 80 
substantial proportion of MDR-LTBI individuals will not have had recognized MDR-TB contacts and standard 81 
preventive therapy could be less effective. All current LTBI diagnostics rely on measuring immune response,9 82 
and cannot determine the strain, nor resistances, of any infecting M.tb. Hence, estimating MDR-LTBI levels can 83 
help inform estimates of standard LTBI therapy efficacy. These estimates can also help guide usage of tailored 84 
preventive treatment for contacts of MDR-TB patients3,12 and setting specific demand for new regimens (which 85 
include levofloxacin and delamanid), currently being tested.13-15  86 
 87 
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In addition, as overall TB incidence and annual risk of infection (ARI) of TB decrease, there will be fewer people 88 
infected with LTBI (DS or MDR) which is thought to partially protect against M.tb reinfection.16-18 If the TB 89 
epidemic becomes increasingly driven by MDR transmission, the presence of an existing “protective” primary 90 
DS-LTBI infection is less likely, which could further facilitate an increasing MDR-TB burden in the younger 91 
generation.19 Hence, a decrease in total LTBI prevalence going forward may facilitate an increased proportion of 92 
LTBI that is MDR.  93 
 94 
No direct data on levels of MDR-LTBI exist as we cannot currently isolate any infecting M.tb bacteria and so 95 
cannot test for resistance. Hence, a modelling approach is the only way to estimate this metric of TB burden. We 96 
developed a new mathematical model which follows cohorts over time, applying historical ARIs estimated by a 97 
previous study4 to track who becomes infected with LTBI. Capturing trends in the proportion of new TB cases 98 
that are MDR as a proxy for the proportion ARI that is MDR,20 allowed us to estimate trends in MDR-M.tb 99 
infection risk and hence the proportion of each cohort with LTBI that carried MDR-M.tb. Using this we could 100 
estimate global MDR-LTBI levels.  101 
102 
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Methods  103 
 104 
Countries included 105 
 106 
138 countries had both data on MDR levels in newly treated patients (survey or surveillance data) from the WHO 107 
Drug Resistance Surveillance (DRS) Project, and were included in the original total LTBI estimates.4 These 108 
countries account for 93% and 96% of the total incident TB and MDR-TB burden in 2016 respectively, and 109 
include 28 of the 30 high MDR-TB burden countries.8 The two high MDR-TB burden countries that we excluded 110 
had no WHO DRS data (Angola and the Democratic Republic of the Congo) and each contributed <1·5% of the 111 
estimated global incident MDR-TB burden in 20168. All details of country selection are given in the appendix. 112 
 113 
Trends in MDR-M.tb annual risk of infection (ARI) 114 
 115 
In order to estimate the burden of MDR-LTBI we needed trends in the annual risk of infection (ARI) with MDR-116 
M.tb. Previous work combined tuberculin skin test (TST) surveys with prevalence data and a revised Styblo rule 117 
to generate ARI with all M.tb for 168 countries.4 A previous systematic review showed that levels of MDR-TB in 118 
children and treatment-naïve adults with TB was a reflection of the current local MDR transmission.20 Hence, we 119 
used the proportion of MDR-TB in new TB cases reported to the WHO as a proxy for the proportion of ARI with 120 
M.tb that was with MDR-M.tb. Fitting trends in the country-level proportions of MDR-TB in new TB cases (see 121 
below) to the WHO DRS data was used to provide 200 samples from the posterior of potential fits. These were 122 
multiplied by the total ARI with M.tb trend estimates from previous work,4 to give ARI with either M.tb strains 123 
not resistant to both rifampicin and isoniazid (drug susceptible, DS-) and MDR-M.tb.  124 
 125 
To capture the changing proportion of new TB cases that are MDR we fitted a flexible statistical model to the 126 
WHO DRS data for MDR levels in new TB cases for each country over time using a Bayesian Markov chain 127 
Monte Carlo (MCMC) approach with the RStan package in R (appendix).21 This model allows for increases, 128 
stabilisation, and also subsequent decreases in the MDR proportion over time. In the absence of extensive 129 
timeseries data (see appendix for a time plot of WHO data), this was fitted with informative priors, reflecting three 130 
data-based assumptions about MDR trend characteristics, to constrain the potential pattern of MDR-TB increase.  131 
 132 
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Firstly, we assumed that it was very unlikely that detectable levels of MDR-TB could have appeared in any 133 
country before 1970 (see appendix for references). To capture this time constraint, the model fitted, for each 134 
country, a time when the proportion of new cases that were MDR-TB was assumed to appear at measurable levels. 135 
The prior for this parameter was normally distributed with a mean of 1985 and a 95% range between 1970 and 136 
2000. This matches a previous modelling study’s assumption that “transmissible” MDR-M.tb strains arose 20-60 137 
years before 2013.22 138 
 139 
Secondly, the rate of increase in proportion of new cases that were MDR was governed by two parameters (b and 140 
c, see appendix) that were scaled to prevent too rapid an increase while still capturing the wide range of MDR 141 
levels (including some very low rates of increase). Thirdly, we ensured that our model did not allow for a "peak 142 
and crash" in the proportion with MDR-TB. The details for the choice of priors and plots of the trends generated 143 
by these assumptions are given in the appendix.  144 
 145 
Estimating LTBI burden 146 
 147 
The estimates of both DS- and MDR-M.tb ARI were inputted into a new cohort model, tracking the proportion of 148 
individuals at each age group infected with DS- or MDR-M.tb (appendix) from 1934 to 2014. The initial 149 
conditions are calculated assuming a constant ARI pre-1934, and there is assumed to be no MDR-TB before 1960 150 
(appendix). We present the estimates of LTBI in 2014 as this is the final time point in the ARI trends.4 Protection 151 
against reinfection is taken to have a mean of 79%.16 We included all available WHO DRS data in the fitting 152 
process, i.e. trends in proportion of new TB that is MDR used WHO MDR-TB data up to 2018 (single data point 153 
from Togo).  154 
 155 
Specifically, the burden we aim to characterise here is of the number of individuals with a persistent immune 156 
response to stimulation by M.tb antigens without evidence of clinically manifested active TB.3 We report the 157 
resistance status of the last infecting strain (e.g. MDR- or DS-M.tb) taking into account protection against 158 
reinfection, ignoring dual infections, and, in the absence of a quantitative alternative, assuming lifelong 159 
infection. 160 
 161 
Recent levels of infection 162 
 8 
 163 
We used model output to estimate the population infected with MDR-M.tb within the last two years (2013-2014) 164 
who would therefore be at a higher risk of progressing to active MDR-TB. These were chosen as these are the last 165 
two years for which we had modelled ARI trends from previous work.4 166 
 167 
Risk ratio by age 168 
 169 
We calculated the risk ratio for those under 15 years old having MDR-LTBI conditional on having LTBI, 170 
compared with those 15 or more years old. We chose 15 years old as the cut-off to match previous LTBI age 171 
segregated estimates and as this is a standard cut-off in TB natural history, as reflected in the WHO data.8 172 
 173 
Burden of disease in 2035 and 2050 174 
 175 
To estimate the contribution of these levels of MDR-LTBI to disease burden in 2035 and 2050, we assumed no 176 
M. tb transmission after 2014. Using UN Population Division demographic projections23 we then estimated the 177 
MDR-LTBI burden in 2035 and 2050 and the level of MDR-TB disease (incidence) assuming a 0.03% per year 178 
remote activation rate, and explored this value in a sensitivity analysis.24 We compared this to the WHO End TB 179 
targets of less than ten TB cases per 100,000 population by 2035, and the Stop TB target of less than one TB case 180 
per million population by 2050.1  181 
 182 
MDR-LTBI data coverage 183 
 184 
To compare how well-informed by resistance data our MDR-LTBI estimates were, we used the cohort model to 185 
determine the proportion of LTBI in 2014 that originated in each 5-year time block in the past (e.g. 20% of those 186 
with LTBI in 2014 were infected in 2000 – 2005 in country X). The sum of all proportions from five year time 187 
blocks that had any WHO DRS data for that country gave the data coverage value (appendix). This gave a metric 188 
that combined the contribution of a time period to MDR-LTBI burden with whether data was present in that time 189 
to compare availability of MDR data by setting. The higher the value, the greater the overlap between contribution 190 
of a time period to MDR-LTBI burden and data availability.  191 
 192 
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Sensitivity analyses  193 
 194 
There is an ongoing debate as to the fitness costs associated with the appearance of resistance within M.tb.25,26 195 
We undertook sensitivity analysis applying a 40% fitness cost25 to the protection from reinfection (from 78% to 196 
47%), and separately to the rate of reactivation (from 0.03% to 0.018%/year), in those with MDR-LTBI. We also 197 
undertook a sensitivity analysis on trend shape: allowing for more flexible dynamics in MDR-ARI in a subset of 198 
countries with sufficient data and a potential “peak and crash” in their proportion of all TB disease that was MDR  199 
(see appendix for details).   200 
 201 
Role of the funding source 202 
 203 
The sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or writing 204 
of the report. The corresponding author had full access to all the data in the study and had final responsibility for 205 
the decision to submit for publication.  206 
 10 
Results  207 
 208 
Trends in levels of MDR-TB 209 
 210 
Model fits for all 138 countries gave estimates of the proportion of new TB cases that are MDR-TB that closely 211 
matched the WHO data (see appendix for individual country trends). Examples of model fits for countries in the 212 
WHO South-East Asia region are shown in figure 1. Here the substantial uncertainty associated with the lack of 213 
data prior to 1990 can be seen, as well as the rising trend in the proportion of new cases that are MDR-TB across 214 
all countries.  215 
 216 
Estimates of MDR-LTBI 217 
We estimate a global prevalence of MDR-LTBI in 2014 of 0·28% [95% uncertainty interval (UI): 0·24-0·31%] 218 
(table 1, figure 2), representing 19 [95% UI: 16-22] million individuals with MDR-LTBI in 2014 (table 2). Of the 219 
global LTBI burden, 1·2% [95% UI: 1·0-1·4%] is due to MDR-M.tb. Combined with our estimates of DS-LTBI 220 
prevalence, total LTBI estimates match previous modelling,4 validating the new cohort model approach used here. 221 
 222 
Geographical heterogeneity in the prevalence of MDR-LTBI was substantial, with the lowest estimate in the 223 
Region of the Americas (0·05% [95% UI: 0·04-0·06%], table 1, figure 2). Variation in the estimates within the 224 
West Pacific Region was large. Reflecting the data showing an increasing proportion of new cases being MDR-225 
TB, across the six regions we estimate that there has been a substantial increase in MDR-LTBI since 1990 (figure 226 
2).  227 
 228 
The estimates for prevalence of MDR-LTBI by country (figure 3 and appendix), show that most countries with 229 
estimates have a prevalence of MDR-TB of less than 1%, whilst countries in Eastern Europe and Central Asia 230 
have a prevalence of above 1·5%. Among the top-30 MDR burden countries, Kazakhstan had the highest 231 
percentage of LTBI that is MDR at 17·5% [95% UI: 6·5-22·9%] (appendix). China (~6 million), India (~4 million) 232 
and Russia (~1·8 million) had the highest absolute numbers of individuals with MDR-LTBI (appendix). 233 
 234 
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In children, the global percentage of LTBI that is MDR (<15 years old) is more than double that in the total 235 
population at 2·9% [95% UI: 2·6-3·1%] (table 1), with the highest relative rate in the European region (14·1% 236 
[95% UI: 13·1-15·2%] in children, vs. 2·8% [95% UI: 1·6-3·9%] in the total population). Aggregating by WHO 237 
region shows that in all regions there is a peak in MDR-M.tb infection between 20 and 35 years old (figure 4). 238 
The risk ratio for MDR-LTBI by age (i.e. the ratio of the proportion of those with LTBI that was MDR in those 239 
< 15 years old vs. those > 15 years old) was 2·65 [95% UI: 2·11-3·25].  240 
 241 
The number of individuals with recent MDR-LTBI infections in the past two years were estimated at 1·9 [95% 242 
UI: 1·7-2·3] million individuals, or 0·03% [95% UI: 0·02%-0·03%] of the global population in 2014. This 243 
population is at high risk of progressing to active MDR-TB. In children, we estimate that 0·6 [95% UI: 0·6-0·8] 244 
million individuals aged < 15 years old were recently infected with MDR-TB in 2014.  245 
 246 
Future projections of MDR-LTBI in 2035 remain high even assuming no ongoing transmission from 2015: 14 247 
[95% UI: 12-16] million, decreasing to 11 [95% UI: 10-12] million by 2050 (see appendix for a map of the 248 
prevalence). MDR-TB disease incidence from this latent pool would be 0·48 [95% UI: 0·42-0·53] per million per 249 
year in 2035 and 0·34 [95% UI: 0·30-0·38] per million per year in 2050. These estimates do not exceed the 2035 250 
WHO End TB or 2050 Stop TB targets (< one TB case per million) by 2050.1 251 
 252 
Metric for data coverage 253 
 254 
The mean and range of the metric for data coverage across all countries and model fits was 0·56 [0 - 1]. Fourteen 255 
countries had median metric values of 1 suggesting that data was available within all contributing time periods. 256 
Four countries had zero metric values as they only had data after 2014. The best data coverage for the 30 high 257 
MDR burden countries was in Russia, Thailand and Uzbekistan (median metric values 0·87 – 0·99), whilst only 258 
one had a median metric value below 0·25: Zimbabwe (appendix). The top four countries in terms of number with 259 
MDR-LTBI (appendix) had median metric values above 0·5.  260 
 261 
Sensitivity analyses 262 
 263 
 12 
Reducing the protective effect of MDR-LTBI to reinfection by 40% resulted in a < 1% difference to all our 264 
results on MDR-LTBI prevalence (appendix). The risk ratio for MDR-LTBI by age decreased slightly to 2·47 265 
[95% UI: 2·03-2.97]. A 40% fitness cost affecting progression from MDR-LTBI to active disease (reactivation) 266 
reduced TB disease incidence from the stable MDR-LTBI pool to 0·29 [95% UI: 0·25-0·32] and 0·20 [95% UI: 267 
0·18-0·23] per million with MDR-TB in 2035 and 2050 respectively. Allowing for more flexible dynamics 268 
resulted in a pre-1995 peak (i.e. before data was available) in the proportion of new TB that is MDR in the three 269 
countries included (China, India and the USA). This increased overall MDR-LTBI estimates but had limited 270 
impact on the MDR-LTBI estimates in those aged less than 15 years (appendix).   271 
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Discussion  272 
 273 
We estimate that in 2014 the global prevalence of MDR-LTBI was 0·28% [95% UI: 0·24-0·31%] with substantial 274 
variation by geography and age group. The proportion of LTBI that is MDR was 1·2% [95% UI: 1·0-1·4%], but 275 
more than double this at 2·9% [95% UI: 2·6-3·1%] in children (< 15 years old). We estimated that if all 276 
transmission stopped in 2015, reactivation cases from MDR-LTBI alone would not exceed the one per million 277 
target for TB elimination by 2050, but would alone contribute approximately a third of the target.1 For all WHO 278 
regions we found that the levels of MDR-LTBI are increasing.  279 
 280 
Our analysis suggests that MDR-LTBI prevalence currently peaks in 20 – 35 year olds. This reflects the 281 
combination of lower LTBI prevalence in younger age groups due to lower cumulative exposure time, but an 282 
increase in the proportion of M.tb infections that are MDR from the early 1990s. A high burden of MDR-LTBI in 283 
children has been estimated previously, but the latter model assumed a constant ARI and did not consider other 284 
age groups.27 We showed that children have double the chance of having LTBI that is MDR compared to adults, 285 
which is worrying given their higher rates of progression to disease and lower probability of appropriate diagnosis 286 
or treatment for MDR-TB compared to adults.28 For future MDR-TB burden, these children also represent a long-287 
persistent reservoir for MDR-TB disease, in the absence of substantial and effective roll-out of new LTBI 288 
preventative therapy programmes. This higher burden is driven by the increasing proportion of ARI that is due to 289 
MDR-TB, within the globally decreasing TB-ARI trend. Hence, children are more likely to be infected with MDR-290 
M.tb bacteria than the current generation of adults were. Indeed, the current generation of adults are partially 291 
“protected” from the current TB-ARI by higher levels of DS-LTBI,16-18 and hence are less likely to have MDR-292 
LTBI. The public health implications of this are that, independently of MDR-TB contacts, LTBI infection cases 293 
in children should be considered at a higher risk of being MDR.  294 
  295 
Our top-ranked WHO global regions by MDR-LTBI prevalence (European and Western Pacific) in 2014 matched 296 
the ranking for proportion of new cases with MDR-TB in the WHO 2018 Global TB report.8 These estimates, 297 
alongside country level values, should help to guide preventative therapy in some settings: high levels of MDR-298 
M.tb infection in LTBI in high incidence settings may suggest that standard LTBI preventative therapy should be 299 
given with even more caution to household contacts and that possible second-line therapies, such as those 300 
currently under trial,13-15 should be considered.  301 
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 302 
Our estimated trends in MDR-LTBI at the WHO regional level were all increasing, as has been estimated 303 
previously for China29 and for isoniazid-resistant latent infection in Lesotho30, despite WHO estimates suggesting 304 
that MDR-TB incidence is currently relatively stable. Our aim was to characterize historical patterns of change in 305 
MDR-ARI to inform MDR-LTBI burden rather than to determine current trajectories in MDR-TB incidence. 306 
 307 
We have created a generalisable approach to combine historical data from country-level with generally 308 
informative priors on MDR appearance to estimate global MDR-LTBI levels. We used informative priors to 309 
capture the timings of isoniazid and rifampicin usage and limited rates of increase to better support the data 310 
available. A strength of our approach is the inclusion of a range of trajectories in the proportion of new TB cases 311 
that are MDR. Our model was also able to track infection by age, which highlights the increasing burden in 312 
younger age groups. We also included sensitivity analyses around the impact of MDR on protection from 313 
reinfection and rate of reactivation, finding that the former had little effect on our results whilst the latter reduced 314 
our predicted MDR-TB incidence by approximately 40% (in line with the assumed parameter reduction). This 315 
highlights the importance of determining this parameter for forecast analysis.  316 
 317 
However, our analysis has several limitations. The first of these is the reliance on historical trends in proportion 318 
of new TB cases that are MDR-TB when little data exists prior to 1990. By setting relatively informative priors 319 
(e.g. very unlikely that MDR arose before 1970) and allowing for both quadratic and linear curves we believe we 320 
have explored a reasonable area of potential MDR trend space and reflect this in our wide uncertainty ranges, but 321 
this was fundamentally limited by the amount and precision of data. We explored this in a sensitivity analysis for 322 
a limited set of high MDR burden countries where data indicated a potential peak in MDR-ARI before data was 323 
available, by fitting more flexible spline models. While this had an impact on our results, it assumed MDR 324 
transmission to rise rapidly from 1970 onwards and pushed the limits of the available data. It is clear, however, 325 
that overall MDR-LTBI prevalence is sensitive to data and assumptions of pre-2000 trends, and future work could 326 
include past trend determination, especially for China (possibly through phylogenetic analysis) as this contributed 327 
most to the observed change in MDR-LTBI prevalence. Our data availability metric shows that most countries in 328 
the top 30 MDR countries had good data availability (median metric values above below 0·5). New drug resistance 329 
surveys or improved surveillance are needed to estimate levels of recent MDR-TB infection that could then be 330 
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used to update our MDR-LTBI estimates. When countries had both survey and surveillance data available, we 331 
also did not treat the data differently (e.g. to account for potential underreporting in surveillance).   332 
 333 
A second limitation is the homogeneity assumed in the model in terms of contact patterns, strain differences, 334 
reactivation rates, spatial variation and population characteristics. By not including differences in mixing patterns 335 
by age, we may have missed some age variation: age assortative mixing, combined with changing disease 336 
presentation31 may result in further differences between children and adults. In terms of strain variation, we did 337 
show that reduced reactivation rates for MDR-TB had a substantial impact on future MDR incidence suggesting 338 
that strain variation differences in reactivation rates could drive differences in MDR incidence globally. For 339 
example, future work could estimate variance in MDR-LTBI prevalence by HIV status, which may have 340 
consequences for assumed fitness costs to resistance and hence greater levels of MDR-LTBI infection in HIV 341 
positive populations. Similarly, we modelled, and averaged surveillance and survey data, at the national level, 342 
which for some settings, such as the Russian Federation, may not be appropriate. 343 
 344 
We also assume lifelong infection, despite the likelihood that self-cure is possible following M.tb infection.19 345 
Indeed most of the LTBI estimates are based on TST and some TST positives may have cleared their M.tb 346 
infection, suggesting that the reservoir of true M.tb infection for reactivation is smaller than estimated LTBI 347 
prevalence (defined through persistent immune response).32 We also present recent infection levels which are 348 
likely to cause the majority of current cases of MDR-TB disease. While our results may overestimate the 349 
population carrying MDR-M.tb, this is accounted for in our estimates of MDR-TB disease driven by reactivation 350 
from MDR-LTBI; the implications for global elimination targets are likely to be robust. We also only modelled 351 
MDR, not all rifampicin resistance, as historical data was on MDR- not rifampicin-resistance levels. 352 
 353 
A further complexity that we did not explore here was mixed infection as the dynamics of reactivation and mixed 354 
strain disease are not fully understood, despite their importance.33 LTBI was assumed to be with the last 355 
successfully infecting strain (e.g. MDR- or DS-M.tb, taking into account protection against reinfection). However, 356 
given the relatively low ARIs in past decades, potential mixed infections make up a low proportion of all MDR-357 
LTBI, and are unlikely to affect the total number of cases carrying MDR- or DS-LTBI.  358 
 359 
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Furthermore, in our main analysis we used a single study estimate for the level of protection against reinfection 360 
progression conferred by LTBI status,16 despite there being other varying estimates available.17,18 This estimate 361 
captures potential risk reductions in infection and/or of progressive TB dependent on LTBI status, which are 362 
currently not possible to separate. We explored the impact of this parameter by lowering the protection again 363 
reinfection for MDR-LTBI in our sensitivity analysis, finding a < 1% change. We did not include a sensitivity 364 
analysis for all LTBI as this result, and the impact in previous work4 of reducing protection from the mean 79% 365 
used here to 50% for all LTBI, was so small. The only impact seen in the previous work4, which was also 366 
reflected in the slightly reduced risk ratio for MDR-LTBI by age in our sensitivity analysis, was on the age 367 
distribution of recent infections, pushing there to be more in older age groups.   368 
 369 
The broader, public health implications of this work are that evidence for the efficacy of current and potential 370 
preventative therapies for those potentially carrying MDR-LTBI needs to be strengthened and the 371 
recommendations possibly made context specific. Our estimates also provide some idea of the value of a 372 
diagnostic test to differentiate between the resistance status of LTBI strains. In terms of future modelling work, 373 
there is a need to quantify the rate and proportion of self-clearance of LTBI to better estimate the size of the 374 
reactivation reservoir. For future transmission, it will be important to explore the impact of any fitness costs 375 
conferred by resistance carriage in M.tb on natural history progression, as well as to better determine the trends 376 
in MDR-M.tb ARI.  377 
 378 
Conclusions 379 
Our estimates suggest that one in every 83 individuals with LTBI carries an MDR-M.tb strain, resulting in nearly 380 
three in every 1,000 people globally carrying MDR-LTBI. However, in children the number with LTBI that is 381 
MDR is one in every 34 and will be higher still in close contacts of those with MDR-TB. Using WHO data on 382 
proportion of new TB cases with MDR, we found that levels of MDR-LTBI are increasing in all WHO regions. 383 
With these current trends, the MDR-LTBI proportion will only increase, posing serious challenges for LTBI 384 
control, a cornerstone of TB elimination strategies. 385 
386 
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Figure Legends  477 
 478 
Figure 1: Median (black line) and 95% uncertainty range (blue shaded area) from 200 model fits to WHO 479 
data (red) for the nine included countries from the WHO South-East Asia region. Results for all countries 480 
are given in the appendix. Note the varying y axis limits and that although we estimated MDR-LTBI burden in 481 
2014 (hence the cut-off shown here) the model trend was fitted to all WHO DRS data.  482 
Figure 2: MDR-LTBI prevalence over time by WHO region. The black line is the median, with shaded red 483 
areas being the 95% uncertainty interval for each region from 200 model fits.  484 
Figure 3: Estimated population prevalence of MDR-LTBI (%). Countries with no data shown in grey. The 485 
same mapping at 2035 and 2050 is shown in the appendix.  486 
Figure 4: The percentage of the population in each age group for each of the six WHO regions with MDR-487 
LTBI. The DS-LTBI levels are shown in the appendix. Error bars indicate 95% uncertainty interval.  488 
489 
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Tables  490 
WHO Region DS-LTBI 
prevalence (%)  
MDR-LTBI 
prevalence (%) 
LTBI that is MDR 
(%) 
LTBI that is MDR in 
<15 year olds (%) 
African  22·1 [20·1-25·5] 0·23 [0·19-0·29] 1·0 [0·8-1·3] 2·3 [1·9-2·7] 
Americas  10·6 [7·3-19·0] 0·05 [0·04-0·06] 0·5 [0·3-0·8] 3·3 [2·8-4·1] 
South-East 
Asia  30·7 [27·7-34·5] 0·31 [0·23-0·41] 1·0 [0·7-1·3] 2·2 [1·9-2·6] 
Eastern 
Mediterranean  16·4 [13·5-20·9] 0·14 [0·08-0·24] 0·9 [0·5-1·5] 2·9 [1·9-3·8] 
Western 
Pacific  26·8 [17·8-39·2] 0·36 [0·26-0·49] 1·3 [0·7-2·2] 3·7 [3·3-4·1] 
European 13·5 [9·9-19·8] 0·38 [0·32-0·44] 2·8 [1·6-3·9] 14·1 [13·1-15·2] 
GLOBAL 22·9 [20·1-26·1] 0·28 [0·24-0·31] 1·2 [1·0-1·4] 2·9 [2·6-3·1] 
 491 
Table 1: Proportion of population infected with Mycobacterium tuberculosis of differing drug resistance 492 
type, by WHO region, in 2014. Brackets indicate 95% uncertainty interval.  493 
494 
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 495 
WHO Region Number with DS-LTBI (thousands) Number with MDR-LTBI (thousands) 
African  155,000 [141,000-179,000] 1,590 [1,310-2,010] 
Americas  102,000 [70,700-183,000] 510 [418-624] 
South-East 
Asia  584,000 [527,000-656,000] 5,810 [4,410-7,750] 
Eastern 
Mediterranean  96,000 [78,900-122,000] 837 [481-1,410] 
Western 
Pacific  493,000 [326,000-720,000] 6,620 [4,840-9,000] 
European 122,000 [90,100-180,000] 3,440 [2,920-3,990] 
GLOBAL 1,580,000 [1,380,000-1,800,000] 19,100 [16,400-21,700] 
 496 
Table 2: Number (thousands) of individuals infected with Mycobacterium tuberculosis of differing drug 497 
resistance type, by WHO region, in 2014. Brackets indicate 95% uncertainty interval. 498 
